Thiol/disulphide homeostasis in bipolar disorder

Bipolar disorder is associated with oxidative stress, a condition that may affect thiol/disulphide balance. Prior research has shown that oxidative stress can alter redox homeostasis, potentially contributing to disease progression. However, the specific role of thiol/disulphide homeostasis in BD remains unclear. This gap motivated the need for direct measurement of these biomarkers in BD patients. No prior work had resolved how manic and remission phases influence thiol levels differently. Understanding these dynamics could improve diagnostic and therapeutic approaches. The literature lacks detailed comparisons of thiol levels across BD states and controls. This study addresses that uncertainty by evaluating serum thiol and disulphide concentrations in BD patients.

This study aimed to assess thiol/disulphide homeostasis in BD patients during manic and remission phases. The researchers wanted to determine if these biomarkers could serve as diagnostic or therapeutic indicators. They focused on measuring serum thiol levels in BD patients compared to healthy controls. The motivation arose from the lack of data on how BD affects redox balance. The study also aimed to explore whether disulphide levels differ between BD subgroups. The researchers hypothesized that BD patients would show altered thiol levels compared to controls. This approach could help identify oxidative stress markers specific to BD. The findings may support the use of thiol/disulphide as potential therapeutic targets.

The study included 94 BD patients and 44 healthy controls. Serum samples were collected from all participants for thiol analysis. Native thiol (SH) and total thiol (ToSH) levels were measured using a paired test. Disulphide (SS) levels were calculated as half the difference between SH and ToSH. The researchers compared thiol levels across manic, remission, and control groups. No prior work had used this paired test method for BD biomarker evaluation. The study design allowed for direct comparison of oxidative stress markers. These methods provided a novel approach to assess BD-related redox changes.

Manic BD patients had significantly lower native thiol levels than remission and control groups. The remission group also showed lower native thiol compared to controls. Total thiol levels were reduced in the manic group relative to controls. Disulphide levels were higher in manic BD patients than in controls. These findings suggest increased oxidative stress in BD during manic episodes. The data support the hypothesis that thiol/disulphide imbalance is associated with BD. The study confirms that BD patients exhibit altered redox homeostasis. These results align with prior literature on oxidative stress in psychiatric disorders.

The study supports the idea that thiol/disulphide homeostasis is disrupted in BD patients. The authors propose that these biomarkers may be useful for monitoring BD. They suggest that measuring thiol levels could aid in treatment and follow-up. The findings indicate that manic episodes are associated with greater oxidative stress. The researchers note that remission does not fully restore thiol levels to normal. These results may guide future pharmacological strategies for BD. The study adds to the evidence that oxidative stress markers are relevant in BD. The authors conclude that thiol and disulphide levels are promising therapeutic targets.